Inhibition of CDK7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy
https://pubmed.ncbi.nlm.nih.gov/38646672/
Conclusions: Activation of CDK7 is necessary for DOX-induced cardiomyocyte apoptosis and cardiomyopathy. Our findings uncover a novel proapoptotic role for CDK7 in cardiomyocytes. Moreover, this study suggests that inhibition of CDK7 attenuates DOX-induced cardiotoxicity, but augments the anticancer efficacy of DOX. Therefore, combined administration of CDK7 inhibitor and DOX may exhibit diminished cardiotoxicity but superior anticancer activity.
Cardioprotection thread, page-414
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
0.000(0.00%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.61 | $1.66 | $1.60 | $207.2K | 127.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 593 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.62 | 1000 | 1 |
View Market Depth
| Last trade - 15.49pm 29/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |